Evaluation of a PCM Mattress to Treat HIE Infants During Transport
NCT ID: NCT05361473
Last Updated: 2024-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
140 participants
INTERVENTIONAL
2013-08-31
2025-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An estimated 3-5 of every 1000 live term births are affected, a quarter of which with severe symptoms; 10-30% of the affected children do not survive, 30% suffer life-long disabilities. The incidence may be 10-fold higher in the developing world. In Sweden, an estimated 200 children are born each year with hypoxic ischemic asphyxia or oxygen deprivation during delivery of a severity necessitating treatment, in order to reduce future handicap. Not only the brain, but also other organs, such as the heart, liver or kidney can be damaged by hypoxic ischemia.
In clinical trials, proof has been obtained that cooling can have positive effects counteracting brain injury induced by oxygen deprivation (asphyxia). Recent research suggests that cooling may also have a positive effect in stroke during the pre-treatment/transportation to hospital phase.
PCM. A material with phase change properties (PCM) can be a chemical element, a solution or a substance with high melting energy. It melts/solidifies at a precise temperature and can store considerable amounts of energy (heat) before changing from one phase to another. The study group have used elements or solutions that change between solid and fluid phases within a narrow temperature interval. The most common use of PCM today is for energy storage, accomplished by having the PCM change between solid and fluid phases. Phase changes that include other PCMs, high temperatures and/or gas phases are less useful in medical applications due to the need of either large volumes in a low pressure setting or smaller amounts in a high pressure setting, increasing the risk for mistakes or secondary injury to medical staff or patients. For the clinical purposes of hypothermic treatment described here, the Glauber salt-based PCM in a mattress form developed by the applicant has near ideal properties; it is completely safe, does not cause over-cooling, can be reused many times, eliminates cooling fluctuations, is easy to handle and biodegradable.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early or Late Cord Clamping in the Depressed Neonate
NCT02727517
Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2
NCT02700854
Effects of Flow Magnitude on Cardiorespiratory Stability During Nasal High Flow Therapy in Preterm Infants
NCT05908227
Late Hypothermia for Hypoxic-Ischemic Encephalopathy
NCT00614744
Intra-operative Feed Back on Traction Force During Vacuum Extraction: Safe Vacuum Extraction Alliance
NCT03071783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An estimated 3-5 of every 1000 live term births are affected, a quarter of which with severe symptoms; 10-30% of the affected children do not survive, 30% suffer life-long disabilities \[1-9\]. The incidence may be 10-fold higher in the developing world. In Sweden, an estimated 200 children are born each year with hypoxic ischemic asphyxia or oxygen deprivation during delivery of a severity necessitating treatment, in order to reduce future handicap. Not only the brain, but also other organs, such as the heart, liver or kidney can be damaged by hypoxic ischemia.
In clinical trials, proof has been obtained that cooling can have positive effects counteracting brain injury induced by oxygen deprivation (asphyxia) \[1-7, 9\]. Recent research suggests that cooling may also have a positive effect in stroke (30000 new cases/year in Sweden) during the pre-treatment/transportation to hospital phase.
PCM. A material with phase change properties (PCM) can be a chemical element, a solution or a substance with high melting energy \[10-13\]. It melts/solidifies at a precise temperature and can store considerable amounts of energy (heat) before changing from one phase to another. The study project have used elements or solutions that change between solid and fluid phases within a narrow temperature interval. The most common use of PCM today is for energy storage, accomplished by having the PCM change between solid and fluid phases. Phase changes that include other PCMs, high temperatures and/or gas phases are less useful in medical applications due to the need of either large volumes in a low pressure setting or smaller amounts in a high pressure setting, increasing the risk for mistakes or secondary injury to medical staff or patients. For the clinical purposes of hypothermic treatment described here, the Glauber salt-based PCM in a mattress form developed by the applicant has near ideal properties; it is completely safe, does not cause over-cooling, can be reused many times, eliminates cooling fluctuations, is easy to handle and biodegradable. III. Methods Whole body cooling with PCM mattresses is straightforward. Rectal temperature will be monitored in standard ways. Several other vital parameters, such as LDH in blood, and standard procedures will be used to monitor condition of the infants continuously. 15 days after treatment, MRI will be carried out at the National Hospital of Pediatrics in Hanoi. Follow up of the treated and control children will be carried out at 18 months of age and will be the bases of the final evaluation of the clinical trial.
Design. The project is based on the applicant's dual expertise in engineering and medicine. The applicant developed a key technology, cooling using a special PCM composition, recently. The applicant has also participated in multicenter hypothermia studies of newborn infants (including the TOBY trial). As part of the PhD program, the applicant has also participated in animal research using a large newborn anesthetized piglet therapeutic hypothermia model in collaboration with Dr. Nicola Robertson and her team at University College of London. These experiences enable design of the current project.
Assessment is done continuously during the first 60 minutes. If criteria A and B are fulfilled, treatment is started before 6 hours of life. Amplitude-integrated EEG is not mandatory to start hypothermia treatment. V. Significance The significance of the research project would be to demonstrate that a novel PCM-technology based method, previously not clinically tested, and could be developed all the way to clinical implementation. In infants, the method has the specific advantage of being easily applied already during transport to a hospital, which makes it possible to begin cooling of many children within the current 6 hr. age limit. If hypoxic ischemic encephalopathy can be prevent fully or partly by hypothermia with PCM, major life-long health improvements for many children worldwide, would result. PCM-based cooling is safe, simple, reusable, environmentally safe, non-toxic, and independent of clean water and electricity and a method where the risk of temperature undershooting causing additional damage is eliminated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The NeoHilda Point of care method
Evaluating baby including lactate dehydregenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
The NeoHilda Point of care method
This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
No Measurement of LDH
Evaluating baby without Lactate dehydrogenase result
Traditional evaluation
Traditional way of evaluation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The NeoHilda Point of care method
This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
Traditional evaluation
Traditional way of evaluation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Gestational age less than 33 weeks postnatal age or above 36 hours after birth
36 Hours
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Children's Hospital, Vietnam
OTHER
Calmark Sweden AB
UNKNOWN
Karolinska Institutet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Linus Olson
Project Investigator, Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hugo Lagercrantz, Professor
Role: STUDY_DIRECTOR
Karolinska Institutet
Khu TK Dung, Prof, Vdir.
Role: PRINCIPAL_INVESTIGATOR
National Hospital of Pediatrics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neonatal unit, National hospital of Pedriatrics
Hanoi, Dong Da, Vietnam
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Karlsson M, Dung KT, Thi TL, Borgstrom E, Jonstam K, Kasstrom L, Winbladh B. Lactate dehydrogenase as an indicator of severe illness in neonatal intensive care patients: a longitudinal cohort study. Acta Paediatr. 2012 Dec;101(12):1225-31. doi: 10.1111/apa.12014.
Karlsson M, Wiberg-Itzel E, Chakkarapani E, Blennow M, Winbladh B, Thoresen M. Lactate dehydrogenase predicts hypoxic ischaemic encephalopathy in newborn infants: a preliminary study. Acta Paediatr. 2010 Aug;99(8):1139-44. doi: 10.1111/j.1651-2227.2010.01802.x. Epub 2010 Mar 19.
Wiberg-Itzel E, Akerud H, Andolf E, Hellstrom-Westas L, Winbladh B, Wennerholm UB. Association between adverse neonatal outcome and lactate concentration in amniotic fluid. Obstet Gynecol. 2011 Jul;118(1):135-142. doi: 10.1097/AOG.0b013e318220c0d4.
Thoresen M, Liu X, Jary S, Brown E, Sabir H, Stone J, Cowan F, Karlsson M. Lactate dehydrogenase in hypothermia-treated newborn infants with hypoxic-ischaemic encephalopathy. Acta Paediatr. 2012 Oct;101(10):1038-44. doi: 10.1111/j.1651-2227.2012.02778.x. Epub 2012 Jul 27.
Tran HTT, Tran DM, Le HT, Hellstrom-Westas L, Alfven T, Olson L. Cooling during transportation of newborns with hypoxic ischemic encephalopathy using phase change material mattresses in low-resource settings: a randomized controlled trial in Hanoi, Vietnam. BMC Pediatr. 2024 Aug 8;24(1):509. doi: 10.1186/s12887-024-04987-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCMcooling test study Vietnam
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.